phensuximide

Trade name: milontin

Small moleculeapproved

Approved

Sep 8, 1953

Phensuximide is an anticonvulsant in the succinimide class. For the treatment of epilepsy. Phensuximide suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in absence (petit mal) seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. Phensuximide's mechanism of action not understood, but may act in inhibitory neuronal systems that are important in the generation of the three per second rhythm. It's effects may be related to its ability to inhibit depolarization-induced accumulation of cyclic AMP and cyclic GMP in brain tissue. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1950s

  1. Sep 8, 1953

    Parke-Davis — Earliest FDA Approval

  2. Sep 8, 1953

    Parke-Davis — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewSep 8, 1953

Chemistry & pharmacology

Loading structure…

SMILES

CN1C(=O)CC(C1=O)C2=CC=CC=C2
Mol. weight
189.2105 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • fensuccimide
  • fensuccimide
  • fensuccimide
  • fensuximida
  • fensuximida
  • milontin
  • milontin
  • milontin
  • phensuccimide
  • phensuccimide
  • phensuccimide
  • phensuccimide
  • phensuccimide
  • phensuccimide
  • phensuximid
  • phensuximide
  • phensuximide
  • phensuximide
  • phensuximide
  • phensuximide
  • phensuximide
  • phensuximide
  • phensuximide
  • phensuximide
  • phensuximide
  • phensuximide, (+-)-isomer
  • phensuximidum
  • phensuximidum
  • racemic phensuximide
  • rs-phensuximide
  • succitimal

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
Parke-DavisFor profitSYNSep 8, 1953
Parke-DavisFor profitNDASep 8, 1953